Shares of Johnson & Johnson (NYSE:JNJ) saw an uptick in trading volume on Tuesday . 6,130,723 shares traded hands during trading, an increase of 3% from the previous session’s volume of 5,966,640 shares.The stock last traded at $120.76 and had previously closed at $122.31.

Several research firms have recently weighed in on JNJ. BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Piper Jaffray Cos. lifted their price objective on Johnson & Johnson from $105.00 to $106.00 and gave the company a “neutral” rating in a report on Wednesday, April 20th. Argus lifted their price objective on Johnson & Johnson from $116.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, April 20th. Finally, Morgan Stanley restated a “hold” rating on shares of Johnson & Johnson in a report on Thursday, May 19th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $119.30.

The company has a 50 day moving average of $123.40 and a 200-day moving average of $113.57. The company has a market cap of $329.15 billion and a price-to-earnings ratio of 22.42.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The company earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Equities research analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 19th. Stockholders of record on Friday, August 5th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 0.96%.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total value of $347,370.00. Following the sale, the chief accounting officer now directly owns 28,725 shares in the company, valued at approximately $3,326,067.75. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. Heritage Wealth Advisors raised its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares during the period. Lourd Capital LLC raised its stake in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock valued at $1,142,000 after buying an additional 851 shares during the period. Eidelman Virant Capital raised its stake in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock valued at $1,193,000 after buying an additional 1,231 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Johnson & Johnson by 9.9% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,032 shares of the company’s stock valued at $1,339,000 after buying an additional 1,179 shares during the period. Finally, Private Capital Management Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at $1,428,000.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.